GraniteShares 2x Long COIN Daily ETF vs Exelixis Inc. Common Stock — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5 (market cap $534.51M), while Exelixis Inc. Common Stock trades at $59.43 (market cap $14.48B). The key difference: Exelixis Inc. Common Stock is far larger — about 27.1× GraniteShares 2x Long COIN Daily ETF's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Exelixis Inc. Common Stock for 0 Days on average.
| CONL | EXEL | |
|---|---|---|
Market Cap | $534.51M | $14.48B |
Volume | 15,212,221 | 2,374,774 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $59.13 |
52-Week Low | $3.93 | $34.54 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $13.81B |
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) is trading at $5.23, down 7.76% with bearish technical signals from moving averages. The ETF tracks Coinbase stock with 2x daily leverage, making it highly volatile. Recent news highlights significant price gaps and performance volatility, with one article noting an 85% decline when Coinbase fell 50%.
The outlook remains high-risk due to leveraged exposure to Coinbase volatility. Investment opportunity exists for speculative traders betting on Coinbase rebounds, but risks include amplified losses, tracking error, and crypto market sentiment swings. Caution is warranted given the bearish technical setup and leveraged structure.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →